{"id":"standard-of-care-plus-pembrolizumab","safety":{"commonSideEffects":[{"rate":"3-5%","effect":"Pneumonitis"},{"rate":"2-3%","effect":"Hypothyroidism"},{"rate":"1-2%","effect":"Hyperthyroidism"},{"rate":"1-2%","effect":"Diarrhea"},{"rate":"1%","effect":"Colitis"},{"rate":"1%","effect":"Arthralgia"},{"rate":"1%","effect":"Myalgia"},{"rate":"1%","effect":"Fatigue"},{"rate":"1%","effect":"Nausea"},{"rate":"<1%","effect":"Vomiting"}]},"_chembl":{"chemblId":"CHEMBL3137343","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to PD-1, pembrolizumab prevents the PD-1 ligands (PD-L1 and PD-L2) from interacting with PD-1, thereby releasing the brakes on the immune system and allowing it to attack cancer cells. This mechanism is thought to be particularly effective in cancers with high levels of PD-L1 expression.","oneSentence":"Pembrolizumab is a monoclonal antibody that blocks the PD-1 receptor, allowing the immune system to attack cancer cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:36:23.117Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer, PD-L1 positive"},{"name":"Head and neck squamous cell carcinoma"},{"name":"Melanoma"},{"name":"Renal cell carcinoma"},{"name":"Classical Hodgkin lymphoma"},{"name":"Urothelial carcinoma"},{"name":"Squamous cell carcinoma of the head and neck"},{"name":"Microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors"},{"name":"Triple-negative breast cancer"},{"name":"Gastric or gastroesophageal junction adenocarcinoma"}]},"trialDetails":[{"nctId":"NCT04284787","phase":"PHASE2","title":"BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-02-16","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia Post Cytotoxic Therapy","enrollment":60},{"nctId":"NCT03620019","phase":"PHASE2","title":"Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma","status":"COMPLETED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2018-09-10","conditions":"Melanoma Stage Iii, Melanoma Stage Iv, Melanoma","enrollment":25},{"nctId":"NCT07465276","phase":"PHASE2","title":"Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable SCC","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2026-03-26","conditions":"Head and Neck Squamous Cell Carcinoma (HNSCC), Squamous Cell Carcinoma of the Head and Neck","enrollment":32},{"nctId":"NCT06295809","phase":"PHASE2, PHASE3","title":"A Study of (Neo)Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-04-18","conditions":"Carcinoma, Squamous Cell, Skin Neoplasms","enrollment":46},{"nctId":"NCT03546686","phase":"PHASE2","title":"Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Triple-negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2019-11-12","conditions":"Breast Cancer","enrollment":51},{"nctId":"NCT05017012","phase":"PHASE1","title":"A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180) [MK-3475A] In Advanced Solid Tumors (MK-3475A-C18)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-09-21","conditions":"Advanced or Metastatic Solid Tumors","enrollment":72},{"nctId":"NCT03712605","phase":"PHASE3","title":"Testing Pembrolizumab Versus Observation in Patients With Merkel Cell Carcinoma After Surgery, STAMP Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-11-15","conditions":"Pathologic Stage I Cutaneous Merkel Cell Carcinoma AJCC v8, Pathologic Stage II Cutaneous Merkel Cell Carcinoma AJCC v8, Pathologic Stage III Cutaneous Merkel Cell Carcinoma AJCC v8","enrollment":280},{"nctId":"NCT02954874","phase":"PHASE3","title":"Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-01-18","conditions":"Invasive Breast Carcinoma, Stage 0 Breast Cancer AJCC v6 and v7, Stage I Breast Cancer AJCC v7","enrollment":1155},{"nctId":"NCT04214249","phase":"PHASE2","title":"BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-02-17","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia Post Cytotoxic Therapy","enrollment":49},{"nctId":"NCT07061977","phase":"PHASE3","title":"Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-11-05","conditions":"Locally Advanced Cervical Adenocarcinoma, Locally Advanced Cervical Adenosquamous Carcinoma, Locally Advanced Cervical Squamous Cell Carcinoma","enrollment":336},{"nctId":"NCT06589804","phase":"PHASE3","title":"Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-03-27","conditions":"Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma, Metastatic Laryngeal Squamous Cell Carcinoma","enrollment":158},{"nctId":"NCT06524544","phase":"PHASE3","title":"A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Standard of Care in the Treatment of Advanced Urothelial Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-12-02","conditions":"Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma","enrollment":320},{"nctId":"NCT04930783","phase":"PHASE1","title":"NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2022-01-03","conditions":"Melanoma, Metastatic Melanoma","enrollment":10},{"nctId":"NCT03197506","phase":"PHASE2","title":"Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mayo Clinic","startDate":"2018-01-15","conditions":"Glioblastoma, Gliosarcoma, Supratentorial Glioblastoma","enrollment":52},{"nctId":"NCT06282575","phase":"PHASE3","title":"Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer","status":"RECRUITING","sponsor":"Jazz Pharmaceuticals","startDate":"2024-07-19","conditions":"Biliary Tract Cancer","enrollment":286},{"nctId":"NCT06462794","phase":"PHASE1","title":"First In Human Study of CX-801 in Advanced Solid Tumors","status":"RECRUITING","sponsor":"CytomX Therapeutics","startDate":"2024-08-28","conditions":"Solid Tumor, Adult","enrollment":121},{"nctId":"NCT06890598","phase":"PHASE3","title":"Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-03-27","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":700},{"nctId":"NCT04462406","phase":"PHASE2","title":"Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2021-02-09","conditions":"Advanced Melanoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8","enrollment":150},{"nctId":"NCT04387084","phase":"PHASE1","title":"Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Southern California","startDate":"2020-08-12","conditions":"Advanced Malignant Skin Neoplasm, Metastatic Malignant Skin Neoplasm","enrollment":10},{"nctId":"NCT05911295","phase":"PHASE3","title":"Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","startDate":"2023-09-22","conditions":"Urothelial Carcinoma","enrollment":412},{"nctId":"NCT05700461","phase":"PHASE1","title":"Drug Screening Using Novel IMD in Renal Cell Carcinoma","status":"ENROLLING_BY_INVITATION","sponsor":"Oliver Jonas","startDate":"2024-12-01","conditions":"Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Kidney Cancer","enrollment":20},{"nctId":"NCT07486687","phase":"PHASE3","title":"Pembrolizumab Adjuvant in Patients With Early-stage Triple Negative Breast Cancer With Residual Disease After Neoadjuvant Pembrolizumab Plus Chemotherapy","status":"NOT_YET_RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2026-04","conditions":"Triple Negative Breast Cancer (TNBC), Early Setting, Early Stage Triple-Negative Breast Carcinoma, Triple -Negative Breast Cancer","enrollment":1000},{"nctId":"NCT07216703","phase":"PHASE3","title":"A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-01-19","conditions":"Cervical Cancer","enrollment":1023},{"nctId":"NCT07485296","phase":"PHASE2","title":"Effect of Postbiotics on Microbiota and Systemic Immunomodulation of Pembrolizumab as First-Line Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (RM HNSCC)","status":"RECRUITING","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2026-01-27","conditions":"Head & Neck Squamous Cell Carcinoma","enrollment":45},{"nctId":"NCT07484022","phase":"PHASE1","title":"Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer","status":"NOT_YET_RECRUITING","sponsor":"Generate Biomedicines","startDate":"2026-03","conditions":"Advanced Urothelial Cancer, Metastatic Urothelial Carcinoma","enrollment":37},{"nctId":"NCT04430699","phase":"PHASE2","title":"Cisplatin+Pembrolizumab+RT in Vulvar Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2020-07-29","conditions":"Vulvar Cancer, Vulvar Squamous Cell Carcinoma","enrollment":24},{"nctId":"NCT07195695","phase":"PHASE3","title":"Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment","status":"RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2026-01-16","conditions":"Non-small Cell Lung Cancer","enrollment":400},{"nctId":"NCT05187182","phase":"PHASE1","title":"CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2023-06-02","conditions":"Gastric Cancer, Esophageal Cancer, Stomach Cancer","enrollment":42},{"nctId":"NCT05098132","phase":"PHASE1, PHASE2","title":"Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers","status":"RECRUITING","sponsor":"Synthekine","startDate":"2022-01-25","conditions":"Advanced Solid Tumor, Non Small Cell Lung Cancer, Untreated Advanced NSCLC","enrollment":364},{"nctId":"NCT06151574","phase":"PHASE3","title":"Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment","status":"RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2024-02-09","conditions":"Lung Cancer, Non-squamous, Non-small Cell","enrollment":416},{"nctId":"NCT06726265","phase":"PHASE3","title":"Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Immutep S.A.S.","startDate":"2025-03-21","conditions":"Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)","enrollment":756},{"nctId":"NCT05422794","phase":"PHASE1","title":"Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-05-18","conditions":"Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Triple-Negative Breast Carcinoma","enrollment":57},{"nctId":"NCT07021989","phase":"PHASE2","title":"ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Michael Spinner, MD","startDate":"2026-05-01","conditions":"Hodgkin Lymphoma, Adult, Refractory Hodgkin Lymphoma, Classic Hodgkin Lymphoma","enrollment":38},{"nctId":"NCT03486873","phase":"PHASE3","title":"Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-08-21","conditions":"Solid Tumors, Hematologic Malignancies","enrollment":3500},{"nctId":"NCT06445972","phase":"PHASE1, PHASE2","title":"Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-08-07","conditions":"Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms","enrollment":210},{"nctId":"NCT07276399","phase":"PHASE3","title":"A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2025-12-03","conditions":"Squamous Cell Carcinoma of Head and Neck","enrollment":500},{"nctId":"NCT01042379","phase":"PHASE2","title":"I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer","status":"RECRUITING","sponsor":"QuantumLeap Healthcare Collaborative","startDate":"2010-03-01","conditions":"Breast Neoplasms, Breast Cancer, Breast Tumors","enrollment":5000},{"nctId":"NCT07287917","phase":"PHASE1, PHASE2","title":"Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors","status":"RECRUITING","sponsor":"Aminex Therapeutics, Inc.","startDate":"2026-01-26","conditions":"Melanoma (Skin Cancer), HER2-low Hormone Receptor Positive Breast Cancer","enrollment":92},{"nctId":"NCT06989112","phase":"PHASE3","title":"DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-03-27","conditions":"Endometrial Cancer","enrollment":600},{"nctId":"NCT06635824","phase":"PHASE3","title":"Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genmab","startDate":"2024-11-25","conditions":"PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC","enrollment":191},{"nctId":"NCT03313804","phase":"PHASE2","title":"Priming Immunotherapy in Advanced Disease With Radiation","status":"COMPLETED","sponsor":"John L. Villano, MD, PhD","startDate":"2017-10-26","conditions":"Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck","enrollment":76},{"nctId":"NCT05239741","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-04-02","conditions":"Colorectal Neoplasms","enrollment":100},{"nctId":"NCT04697576","phase":"PHASE1","title":"Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma","status":"RECRUITING","sponsor":"Carlo Contreras","startDate":"2021-10-20","conditions":"Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage IA Cutaneous Melanoma AJCC v8, Clinical Stage IB Cutaneous Melanoma AJCC v8","enrollment":36},{"nctId":"NCT03523702","phase":"PHASE2","title":"The Selective Personalized Radio-Immunotherapy for Locally Advanced NSCLC Trial","status":"COMPLETED","sponsor":"Albert Einstein College of Medicine","startDate":"2018-08-30","conditions":"Non-small Cell Lung Cancer, NSCLC","enrollment":25},{"nctId":"NCT07455032","phase":"PHASE1","title":"Neoadjuvant CADI-05 in Combination With Pembrolizumab for Surgically Resectable Locally Advanced Head and Neck Squamous Cell Carcinomas","status":"NOT_YET_RECRUITING","sponsor":"Fox Chase Cancer Center","startDate":"2026-03-02","conditions":"Squamous Cell Carcinoma of Head and Neck","enrollment":22},{"nctId":"NCT04222972","phase":"PHASE3","title":"A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2020-07-24","conditions":"RET-fusion Non Small Cell Lung Cancer, Lung Neoplasm, Carcinoma, Non-Small-Cell Lung","enrollment":223},{"nctId":"NCT05934448","phase":"PHASE2","title":"Pembro Plus CAR T-cell Therapy in R/R in PMBCL","status":"RECRUITING","sponsor":"Jennifer Crombie, MD","startDate":"2023-11-15","conditions":"Primary Mediastinal Large B-cell Lymphoma (PMBCL), Primary Mediastinal Large B Cell Lymphoma, Primary Mediastinal Large B-Cell Lymphoma Refractory","enrollment":35},{"nctId":"NCT03313778","phase":"PHASE1","title":"Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"ModernaTX, Inc.","startDate":"2017-08-14","conditions":"Solid Tumors","enrollment":161},{"nctId":"NCT06868433","phase":"PHASE1","title":"TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer","status":"RECRUITING","sponsor":"Emory University","startDate":"2025-05-08","conditions":"Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma","enrollment":40},{"nctId":"NCT05467670","phase":"PHASE2","title":"Safety and Efficacy of Anti-CD47, ALX148 in Combination With Liposomal Doxorubicin and Pembrolizumab in Recurrent Platinum-resistant Ovarian Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alexander B Olawaiye, MD","startDate":"2023-03-30","conditions":"Ovarian Cancer","enrollment":16},{"nctId":"NCT06047379","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis","status":"RECRUITING","sponsor":"Neonc Technologies, Inc.","startDate":"2023-11-01","conditions":"Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult","enrollment":134},{"nctId":"NCT06452277","phase":"PHASE3","title":"A Study to Learn More About How Well Sevabertinib (BAY 2927088) Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)","status":"RECRUITING","sponsor":"Bayer","startDate":"2024-08-28","conditions":"Advanced Non-small Cell Lung Cancer, HER2 Mutation","enrollment":278},{"nctId":"NCT06772623","phase":"PHASE1, PHASE2","title":"Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations","status":"RECRUITING","sponsor":"AbbVie","startDate":"2025-03-06","conditions":"Non Small Cell Lung Carcinoma","enrollment":252},{"nctId":"NCT06745882","phase":"PHASE2","title":"Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2025-06-13","conditions":"Non-small Cell Lung Cancer","enrollment":318},{"nctId":"NCT03774732","phase":"PHASE3","title":"PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2018-01-24","conditions":"Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic, Non-Small Cell Carcinoma of Lung, TNM Stage 4","enrollment":327},{"nctId":"NCT07192926","phase":"","title":"Sarcopenia and CRP-TyG Index (CTI) as Predictors of Immunotherapy Response in Metastatic Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Ankara Etlik City Hospital","startDate":"2022-11-15","conditions":"Metastatic Non-small Cell Lung Cancer, Neoplasm","enrollment":131},{"nctId":"NCT06475235","phase":"PHASE1","title":"Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2024-10-18","conditions":"Lymphoma, Primary Central Nervous System Lymphoma","enrollment":15},{"nctId":"NCT04221945","phase":"PHASE3","title":"Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-05-12","conditions":"Uterine Cervical Neoplasms","enrollment":1060},{"nctId":"NCT06731907","phase":"PHASE2","title":"A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-03-30","conditions":"Non-small Cell Lung Cancer","enrollment":90},{"nctId":"NCT06470282","phase":"PHASE1, PHASE2","title":"Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder Cancer","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2025-03-31","conditions":"Bladder Cancer, Muscle-Invasive Bladder Carcinoma, Stage II Bladder Cancer AJCC v8","enrollment":47},{"nctId":"NCT07166601","phase":"PHASE1","title":"M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors","status":"RECRUITING","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2025-10-10","conditions":"Advanced Solid Tumor","enrollment":77},{"nctId":"NCT02422381","phase":"PHASE1, PHASE2","title":"MK-3475 and Gemcitabine in Non-Small Cell Lung Cancer (NSCLC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Providence Health & Services","startDate":"2015-07-20","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":16},{"nctId":"NCT05487859","phase":"PHASE2","title":"Acarbose in Combination With Standard Therapy in Metastatic Renal Cell Carcinoma (RCC)","status":"WITHDRAWN","sponsor":"University of Alabama at Birmingham","startDate":"2025-12-31","conditions":"Kidney Cancer","enrollment":""},{"nctId":"NCT06138561","phase":"","title":"Management of Cisplatin-Ineligible Patients With Metastatic Bladder Cancer and The Role of Geriatric Assessments","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2024-03-05","conditions":"Bladder Cancer, Metastatic Bladder Cancer, Unresectable Bladder Carcinoma","enrollment":180},{"nctId":"NCT07300475","phase":"PHASE1","title":"Cancer Immunotherapeutic (PCI) Strategy in Triple Negative Breast Cancer Patients","status":"NOT_YET_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2026-03-31","conditions":"Triple Negative Breast Cancer","enrollment":30},{"nctId":"NCT06764095","phase":"PHASE4","title":"Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2025-01-08","conditions":"Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis and Ureter Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma","enrollment":75},{"nctId":"NCT06731270","phase":"PHASE2","title":"Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy","status":"RECRUITING","sponsor":"Emory University","startDate":"2025-04-09","conditions":"Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8","enrollment":20},{"nctId":"NCT07407920","phase":"PHASE2","title":"Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2025-10-09","conditions":"Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Early Stage HER2-Positive Breast Carcinoma","enrollment":120},{"nctId":"NCT05993234","phase":"","title":"A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY)","status":"RECRUITING","sponsor":"Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company","startDate":"2023-12-05","conditions":"HER2-positive Advanced Gastric Cancer, HER2-positive Gastroesophageal Junction Adenocarcinoma","enrollment":257},{"nctId":"NCT06135714","phase":"PHASE3","title":"Metastasis-directed Therapy for Oligometastases of Breast Cancer","status":"RECRUITING","sponsor":"Tokyo Medical and Dental University","startDate":"2023-11-08","conditions":"Breast Cancer, Oligometastasis, Metastatic Breast Cancer","enrollment":340},{"nctId":"NCT07326137","phase":"","title":"A Prospective Observational Study of First-Line Systemic Therapy Combined With Celiac Plexus Blockade for Advanced Biliopancreatic Cancer With Pain","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-12-26","conditions":"Advanced Biliary Tract Cancer(BTC), Advanced Pancreatic Cancers, Cancer-related Pain","enrollment":103},{"nctId":"NCT07404332","phase":"PHASE1","title":"5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors","status":"NOT_YET_RECRUITING","sponsor":"Mohammed Milhem","startDate":"2026-02-28","conditions":"Solid Tumor, Locally Advanced Solid Tumor, Metastatic Tumor","enrollment":35},{"nctId":"NCT06366347","phase":"PHASE2","title":"ALPINE: Maintenance Letrozole/Abemaciclib","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2024-09-25","conditions":"Endometrial Cancer, Recurrent Endometrial Cancer, TP53","enrollment":32},{"nctId":"NCT05358938","phase":"EARLY_PHASE1","title":"Exercise to Boost Response to Checkpoint Blockade Immunotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2022-06-21","conditions":"Cutaneous Melanoma, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma","enrollment":22},{"nctId":"NCT07394062","phase":"","title":"Real-World Comparison of Chemo-Immunotherapy Regimens in Metastatic NSCLC With PD-L1 <50% (ALCG-01)","status":"RECRUITING","sponsor":"Gazi University","startDate":"2026-02","conditions":"Nonsmall Cell Lung Cancer, Stage IV, Metastatic Nonsmall Cell Lung Cancer","enrollment":400},{"nctId":"NCT06939036","phase":"PHASE1, PHASE2","title":"Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 )","status":"TERMINATED","sponsor":"Ariceum Therapeutics GmbH","startDate":"2025-07-01","conditions":"Small Cell Lung Cancer Extensive Stage, Merkel Cell Carcinoma","enrollment":2},{"nctId":"NCT04700124","phase":"PHASE3","title":"Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-04-21","conditions":"Bladder Cancer","enrollment":808},{"nctId":"NCT04776148","phase":"PHASE3","title":"Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-03-29","conditions":"Colorectal Neoplasms","enrollment":563},{"nctId":"NCT03727880","phase":"PHASE2","title":"Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma","status":"COMPLETED","sponsor":"Lei Zheng","startDate":"2019-06-04","conditions":"Resectable Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Ductal Adenocarcinoma","enrollment":28},{"nctId":"NCT05815927","phase":"PHASE3","title":"Pembrolizumab and Radiotherapy for Oligometastatic Head and Neck Cancer","status":"RECRUITING","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2025-05-23","conditions":"Oligometastatic Squamous Cell Carcinoma of the Head and Neck","enrollment":200},{"nctId":"NCT07183319","phase":"PHASE2","title":"Circulating Tumor DNA Response In Urothelial Cancer","status":"RECRUITING","sponsor":"University of Oklahoma","startDate":"2026-01-19","conditions":"Urothelial Carcinoma","enrollment":30},{"nctId":"NCT06381154","phase":"PHASE2","title":"Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2024-12-06","conditions":"Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8","enrollment":25},{"nctId":"NCT03474497","phase":"PHASE1, PHASE2","title":"UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade","status":"ACTIVE_NOT_RECRUITING","sponsor":"Megan Daly, MD","startDate":"2019-05-20","conditions":"Non Small Cell Lung Cancer, Metastatic Melanoma, Metastatic Renal Cell Carcinoma","enrollment":18},{"nctId":"NCT05366166","phase":"PHASE2","title":"Pembrolizumab Plus Olaparib in LA-HNSCC","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2022-09-02","conditions":"Squamous Cell Carcinoma of Head and Neck","enrollment":45},{"nctId":"NCT07368985","phase":"PHASE2","title":"Pembrolizumab and Lenvatinib in Patients With High Risk Locally Advanced Cervix Cancer","status":"NOT_YET_RECRUITING","sponsor":"Prof. Dr. Remi A. Nout","startDate":"2026-03","conditions":"Cervical Cancer by FIGO Stage 2018, Squamous Cell Carcinoma FIGO 2018 Stage IIIA, IIIB, IIIC1-IIIC2, Adenocarcinoma or Adeno-squamous Carcinoma Stage IB3-IIIC2","enrollment":87},{"nctId":"NCT05553782","phase":"EARLY_PHASE1","title":"Drug Screening Using Novel IMD in Salivary and Head and Neck Cancers","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2023-11-01","conditions":"Salivary Gland Cancer, Adenoid Cystic Carcinoma of the Salivary Gland, Squamous Cell Carcinoma of Head and Neck","enrollment":30},{"nctId":"NCT07365319","phase":"PHASE2, PHASE3","title":"A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.","status":"NOT_YET_RECRUITING","sponsor":"Eikon Therapeutics","startDate":"2026-05-18","conditions":"Non Small Cell Lung Cancer (Squamous or Non Squamous), Stage 4 NSCLC","enrollment":750},{"nctId":"NCT06599619","phase":"","title":"Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Atypical/Dysplastic Nevi","status":"RECRUITING","sponsor":"John Kirkwood","startDate":"2025-02-20","conditions":"Melanoma","enrollment":30},{"nctId":"NCT04701918","phase":"PHASE2","title":"Cryoablation With Pembrolizumab Or Avelumab In Urothelial Carcinoma","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2021-06-04","conditions":"Metastatic Urothelial Carcinoma, Bladder Cancer","enrollment":9},{"nctId":"NCT07347210","phase":"PHASE2","title":"Evaluation of UCPVax Vaccine +/- Pembrolizumab Combined With Standard Treatment as Adjuvant Therapy in Patients With Unmethylated MGMT Glioblastoma","status":"NOT_YET_RECRUITING","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"2026-01","conditions":"Primary Glioblastoma","enrollment":98},{"nctId":"NCT07346053","phase":"PHASE3","title":"The Impact of Time-of-day Administration of EV/P on Objective Response Rate in Adults With Advanced Bladder Cancer","status":"NOT_YET_RECRUITING","sponsor":"Guliz Ozgun","startDate":"2026-05","conditions":"Advanced Bladder Cancer","enrollment":224},{"nctId":"NCT07231458","phase":"PHASE1","title":"A Study to Test a New Immunotherapy, ABX-001, Alone and in Combination With the Marketed Drug, Pembrolizumab, for the Treatment of Tumors Previously Treated With Other Therapies","status":"RECRUITING","sponsor":"Abalos Therapeutics GmbH","startDate":"2025-10-14","conditions":"Advanced Solid Tumors","enrollment":27},{"nctId":"NCT06353997","phase":"PHASE2","title":"Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients","status":"RECRUITING","sponsor":"Providence Health & Services","startDate":"2024-09-05","conditions":"Triple Negative Breast Cancer","enrollment":12},{"nctId":"NCT02296684","phase":"PHASE2","title":"Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2015-03-25","conditions":"Cancer of Head and Neck, Head and Neck Cancer, Neoplasms, Head and Neck","enrollment":67},{"nctId":"NCT05327686","phase":"PHASE2","title":"Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2023-02-01","conditions":"Metastatic Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8","enrollment":240},{"nctId":"NCT06242834","phase":"PHASE2","title":"Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma","status":"RECRUITING","sponsor":"Northwestern University","startDate":"2024-09-30","conditions":"B-Cell Non-Hodgkin Lymphoma","enrollment":32},{"nctId":"NCT07341867","phase":"PHASE1","title":"Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype","status":"NOT_YET_RECRUITING","sponsor":"Andrew Hantel, MD","startDate":"2026-06","conditions":"Multiple Myeloma, Triple Negative Breast Cancer, Duffy Blood Group, Chemokine Receptor Gene Mutation","enrollment":90},{"nctId":"NCT05777603","phase":"PHASE1","title":"Study of Aerosolized Antibiotics and Pembrolizumab in Advanced Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-04-18","conditions":"Advanced Non Small Cell Lung Cancer","enrollment":23},{"nctId":"NCT06236425","phase":"PHASE1","title":"TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2024-03-14","conditions":"Squamous Cell Carcinoma of Head and Neck, Metastatic Squamous Cell Carcinoma","enrollment":7},{"nctId":"NCT05405595","phase":"PHASE1, PHASE2","title":"ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Adagene Inc","startDate":"2022-06-15","conditions":"Advanced/Metastatic Solid Tumors","enrollment":186}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["KEYTRUDA"],"phase":"phase_3","status":"active","brandName":"Standard of care plus pembrolizumab","genericName":"Standard of care plus pembrolizumab","companyName":"The Netherlands Cancer Institute","companyId":"the-netherlands-cancer-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Pembrolizumab is a monoclonal antibody that blocks the PD-1 receptor, allowing the immune system to attack cancer cells. Used for Non-small cell lung cancer, PD-L1 positive, Head and neck squamous cell carcinoma, Melanoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}